首页> 美国卫生研究院文献>Journal of Veterinary Science >Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine
【2h】

Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine

机译:用多价DNA疫苗预防鸡感染传染性支气管炎病毒并用灭活疫苗加强免疫

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The protective efficacy of DNA plasmids encoding avian infectious bronchitis virus (IBV) S1, N, or M protein was investigated in chickens. Chickens were inoculated monovalently (with plasmid pVAX1-16S1, pVAX1-16M, or pVAX1-16N alone) or multivalently (combination of the three different plasmids, pVAX1-16S1/M/N). A prime-boost immunization protocol against IBV was developed. Chickens were immunized with the multivalent DNA vaccine twice and then boosted with an inactivated vaccine once. Antibody titers of the chickens immunized with pVAX1-16S1/M/N were much higher than those of the monovalent groups (p < 0.01). A protective rate up to 90% was observed in the pVAX1-16S1/M/N group. The serum antibody titers in the prime-boost birds were significantly higher than those of the multivalent DNA vaccine group (p < 0.01) but not significantly different compared to the inactivated vaccine group at 49 days of age. Additionally, the prime-boost group also showed the highest level of IBV-specific cellular proliferation compared to the monovalent groups (p < 0.01) but no significant difference was found compared to the multivalent DNA vaccine group, and the prime-boost group completely protected from followed viral challenge.
机译:在鸡中研究了编码禽传染性支气管炎病毒(IBV)S1,N或M蛋白的DNA质粒的保护功效。将鸡单价接种(单独使用质粒pVAX1-16S1,pVAX1-16M或pVAX1-16N)或多价接种(三种不同质粒pVAX1-16S1 / M / N的组合)。制定了针对IBV的初免-加强免疫方案。鸡用多价DNA疫苗免疫了两次,然后用灭活疫苗进行了加强免疫。用pVAX1-16S1 / M / N免疫的鸡的抗体滴度远高于单价组(p <0.01)。在pVAX1-16S1 / M / N组中观察到高达90%的保护率。初免-加强型禽类的血清抗体滴度显着高于多价DNA疫苗组(p <0.01),但与49天龄灭活疫苗组相比无显着差异。此外,与单价组相比,初免-增压组还显示出最高水平的IBV特异性细胞增殖(p <0.01),但与多价DNA疫苗组相比,没有发现显着差异,并且初免-增压组得到了完全保护来自随后的病毒挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号